Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bendamustine Plus Rituximab (BR) in Relapsed or Progressive MZBCL
NCT02433795Phase 2Completed
- Sponsor
- Seoul National University Hospital
- Start
- May 2015
- Primary completion
- Oct 2019
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bendamustine, rituximab in marginal zone B-cell lymphoma (MZL), sponsored by Seoul National University Hospital. Started May 2015; status: completed.
02
Drugs
bendamustinerituximab
03
Conditions
marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on NCT02433795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02433795.